Community activists have worked for the past two years to get Glaxo to create a program with a better chance of success. Since abacavir is expected to receive FDA marketing clearance by this fall, the new program will not last long. The syndrome is aggravating enough to force interruption of treatment and can rapidly return in life-threatening proportions if abacavir is restarted after the initial symptoms subside. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.